Solid Tumors
A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE2016, an Allogeneic Anti-EGFR Conjugated Gamma Delta T-Cell (gdT) Therapy in Adult Subjects with Locally Advanced or Metastatic Solid Tumors Expressing the Epidermal Growth Factor Receptor (EGFR)(ACE2016-001)
- Details
ClinicalTrials.gov ID:
NCT06415487
Diagnosis Type:
NA
USOR Number:
- Address
,
P: